[HTML][HTML] Interrupting endocrine therapy to attempt pregnancy after breast cancer
…, AB Sætersdal, JR Kroep, A Mailliez… - New England journal …, 2023 - Mass Medical Soc
Background Prospective data on the risk of recurrence among women with hormone
receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt …
receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt …
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations …
Purpose: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced
breast cancer. Patients and Methods: ABRAZO (NCT02034916) was a two-cohort, two-…
breast cancer. Patients and Methods: ABRAZO (NCT02034916) was a two-cohort, two-…
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and …
…, V Diéras, DA Yardley, DA Potter, A Mailliez… - The Lancet …, 2015 - thelancet.com
Background New options are needed for patients with heavily pretreated breast cancer.
Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but …
Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but …
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer
E Le Rhun, J Wallet, A Mailliez, MC Le Deley… - Neuro …, 2020 - academic.oup.com
Background DEPOSEIN (NCT01645839) was a randomized open-label phase III study to
explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal …
explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal …
[HTML][HTML] Who are the women who enrolled in the POSITIVE trial: a global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
…, C Shimizu, AB Sætersdal, JR Kroep, A Mailliez… - The Breast, 2021 - Elsevier
… Kroep j , Audrey Mailliez k , Ellen Warner l , Virginia F. Borges m , Frédéric Amant n o , …
Audrey Mailliez reports no trial related conflicts. Ellen Warner reports no conflicts related to …
Audrey Mailliez reports no trial related conflicts. Ellen Warner reports no conflicts related to …
Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1 …
1007 Background: TALA is a dual-mechanism PARP inhibitor that traps PARP on DNA. This
study was designed to assess the activity of TALA in pts with gBRCA1/2mutation previously …
study was designed to assess the activity of TALA in pts with gBRCA1/2mutation previously …
Comparison of management and outcomes in ERBB2-low vs ERBB2-zero metastatic breast cancer in France
O de Calbiac, A Lusque, A Mailliez… - JAMA network …, 2022 - jamanetwork.com
Importance ERBB2-low (ie,ERBB2immunohistochemistry score of 1+ or 2+ in the absence
ofERBB2gene amplification) breast cancer (BC) is a new entity, with emerging dedicated …
ofERBB2gene amplification) breast cancer (BC) is a new entity, with emerging dedicated …
Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
…, AN Tutt, W Audeh, M Ignatiadis, A Mailliez… - Clinical Cancer …, 2021 - AACR
Purpose: To investigate the activity of niraparib in patients with germline-mutated BRCA1/2 (gBRCAm)
advanced breast cancer. Patients and Methods: BRAVO was a randomized, open-…
advanced breast cancer. Patients and Methods: BRAVO was a randomized, open-…
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON …
…, V Diéras, DA Yardley, DA Potter, A Mailliez… - Breast cancer research …, 2017 - Springer
Purpose Conventional chemotherapy has limited activity in patients with breast cancer and
brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 …
brain metastases (BCBM). Etirinotecan pegol (EP), a novel long-acting topoisomerase-1 …
Survival impact of locoregional treatment of the primary tumor in de novo metastatic breast cancers in a large multicentric cohort study: a propensity score-matched …
…, M Campone, J Geffrelot, C Mazouni, A Mailliez… - Annals of Surgical …, 2019 - Springer
Introduction Improvement in overall survival (OS) by locoregional treatment (LRT) of the
primary tumor in de novo metastatic breast cancer (MBC) patients remains controversial. …
primary tumor in de novo metastatic breast cancer (MBC) patients remains controversial. …
